Product Information
CARISOPRODOL 250 MG TABLET is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.4739 per EA under NDC 51525590101. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
250 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
51525590101
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CARISOPRODOLApproval Type
Authorized Generic (NDA)
FDA Application
NDA011792FDA Approved
Before 1982
TE Code
AB
On Market Since
10/1/2016
Pharmacological Classes
Price Statistics
The NADAC for CARISOPRODOL 250 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 81.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4739 per EA |
|---|---|
| All-time high | $2.7381 (Mar 15, 2017) |
| All-time low | $0.3644 (Jul 22, 2026) |
| 52-week high | $0.5508 |
| 52-week low | $0.3644 |
| Median price | $1.2983 |
| Average price | $1.4573 |
| Largest weekly change | +80.1% (Aug 17, 2022) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
carisoprodol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Muscle Relaxant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CARISOPRODOL 250 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CARISOPRODOL 250 MG TABLET, manufactured by Mylan Pharmaceuticals Inc., is $0.4739 per EA (NDC 51525590101), effective Sep 30, 2026.
How has the price of CARISOPRODOL 250 MG TABLET changed over time?
Over the history we have for it, the NADAC for CARISOPRODOL 250 MG TABLET has declined 81.6%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CARISOPRODOL 250 MG TABLET?
Since Nov 28, 2013, the NADAC for CARISOPRODOL 250 MG TABLET has ranged from a low of $0.3644 (Jul 22, 2026) to a high of $2.7381 (Mar 15, 2017), with a median of $1.2983 per EA.
Are there cheaper alternatives to CARISOPRODOL 250 MG TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CARISOPRODOL 250 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures CARISOPRODOL 250 MG TABLET?
CARISOPRODOL 250 MG TABLET (NDC 51525590101) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.